subscribeSubscribe
AASLD: Gilead wants to move the needle for fatty liver therapies

AASLD: Gilead wants to move the needle for fatty liver therapies
A. A Idrus FIERCE BIOTECH
11 Nov 2019
Share Share
Gilead experimental NASH drug fails another study

Gilead experimental NASH drug fails another study
Manas Mishra REUTERS
26 Apr 2019
Share Share
Gilead teams up with Insitro for experimental NASH treatments

Gilead teams up with Insitro for experimental NASH treatments
Saumya S. Joseph REUTERS
17 Apr 2019
Share Share
Pipeline revamp. Forward thrust. What does a decade of deals at Gilead

Pipeline revamp. Forward thrust. What does a decade of deals at Gilead
John Carroll ENDPTS
04 Mar 2019
Share Share
Gilead Announces Topline Data From Ph 3 Study of Selonsertib in NASH

Gilead Announces Topline Data From Ph 3 Study of Selonsertib in NASH
BUSINESSWIRE
12 Feb 2019
Share Share
Gilead misses key goal in NASH liver disease trial, shares sink

Gilead misses key goal in NASH liver disease trial, shares sink
Julie Steenhuysen REUTERS
12 Feb 2019
Share Share
What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?

What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?
John Carroll ENDPTS
24 Jan 2019
Share Share
Is 2019 The Turnaround Year For Gilead Sciences?

Is 2019 The Turnaround Year For Gilead Sciences?
SEEKING ALPHA
14 Jan 2019
Share Share
At JPM, the NASH flood gates start to crack

At JPM, the NASH flood gates start to crack
Jacob Bell BIOPHARMA DIVE
12 Jan 2019
Share Share
Gilead stuffs another NASH drug discovery program into a growing portfolio

Gilead stuffs another NASH drug discovery program into a growing portfolio
John Carroll ENDPTS
04 Jan 2019
Share Share